U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C21H17ClFNO
Molecular Weight 353.817
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of EO-1606

SMILES

CC1=C(C=CC=C1)C(=O)C2=CC=C(NC3=C(C)C=C(F)C=C3)C=C2Cl

InChI

InChIKey=QIBLVZMAUUVSMB-UHFFFAOYSA-N
InChI=1S/C21H17ClFNO/c1-13-5-3-4-6-17(13)21(25)18-9-8-16(12-19(18)22)24-20-10-7-15(23)11-14(20)2/h3-12,24H,1-2H3

HIDE SMILES / InChI

Molecular Formula C21H17ClFNO
Molecular Weight 353.817
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Approval Year

Substance Class Chemical
Created
by admin
on Sat Dec 16 11:40:35 GMT 2023
Edited
by admin
on Sat Dec 16 11:40:35 GMT 2023
Record UNII
WX9Y9W9AAY
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
EO-1606
Code English
METHANONE, (2-CHLORO-4-((4-FLUORO-2-METHYLPHENYL)AMINO)PHENYL)(2-METHYLPHENYL)-
Systematic Name English
(2-CHLORO-4-((4-FLUORO-2-METHYLPHENYL)AMINO)PHENYL)(2-METHYLPHENYL)METHANONE
Systematic Name English
EO1606
Code English
(2-CHLORO-4-(4-FLUORO-2-METHYL-ANILINO)PHENYL)-(O-TOLYL)METHANONE
Systematic Name English
Code System Code Type Description
CAS
344457-87-0
Created by admin on Sat Dec 16 11:40:35 GMT 2023 , Edited by admin on Sat Dec 16 11:40:35 GMT 2023
PRIMARY
PUBCHEM
9798659
Created by admin on Sat Dec 16 11:40:35 GMT 2023 , Edited by admin on Sat Dec 16 11:40:35 GMT 2023
PRIMARY
FDA UNII
WX9Y9W9AAY
Created by admin on Sat Dec 16 11:40:35 GMT 2023 , Edited by admin on Sat Dec 16 11:40:35 GMT 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY
Originator: LEO Pharma; Class: Anti-inflammatory; Mechanism of Action: Immunosuppressant; Highest Development Phase: Discontinued for Dermatitis; Most Recent Event: 13 May 2003 Discontinued - Phase-II for Dermatitis in Europe (unspecified route) EO-1606 is a topical anti-inflammatory agent that was under development with the Danish company LEO Pharma A/S (formerly Leo Pharmaceutical Products).